Sean McLoughlin, GlaxoSmithKline
S
Sean McLoughlin
Product director, diabetes franchise, GlaxoSmithKline
BORN IN: Belfast, Ireland
PEOPLE ARE: "Your long term strategic advantage"
On the tough times ahead:
In five or 10 years, some companies will be here and some will not—and it is the leadership of the company that will determine that. The irony is that it will require a lot of investment in both capital and human resources to be successful at a time when maybe those investments are more likely to drop. It is going to take courage to figure out just what are the key issues, where the company needs to go, and then make those expenditures into the long term health of the company.
Sean McLoughlin
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
